Diabetic Neuropathy: A Guide to Pain Management.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY Current Pain and Headache Reports Pub Date : 2024-10-01 Epub Date: 2024-07-05 DOI:10.1007/s11916-024-01293-9

Emily X Zhang, Cyrus Yazdi, Rahib K Islam, Ahmed I Anwar, Alana Alvares-Amado, Horace Townsend, Kaitlyn E Allen, Elena Plakotaris, Jon D Hirsch, Ross G Rieger, Varsha Allampalli, Jamal Hasoon, Kazi N Islam, Sahar Shekoohi, Alan D Kaye, Christopher L Robinson

{"title":"Diabetic Neuropathy: A Guide to Pain Management.","authors":"Emily X Zhang, Cyrus Yazdi, Rahib K Islam, Ahmed I Anwar, Alana Alvares-Amado, Horace Townsend, Kaitlyn E Allen, Elena Plakotaris, Jon D Hirsch, Ross G Rieger, Varsha Allampalli, Jamal Hasoon, Kazi N Islam, Sahar Shekoohi, Alan D Kaye, Christopher L Robinson","doi":"10.1007/s11916-024-01293-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.Recent findings: Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.","PeriodicalId":50602,"journal":{"name":"Current Pain and Headache Reports","volume":" ","pages":"1067-1072"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pain and Headache Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11916-024-01293-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.

Recent findings: Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

糖尿病神经病变：疼痛管理指南》。

审查目的：糖尿病神经病变是糖尿病（DM）的常见并发症，多达 50% 的糖尿病患者终生都会受到影响。患者通常表现为四肢麻木、刺痛、疼痛和感觉丧失。由于目前还没有针对神经病变根本机制的治疗方法，因此治疗策略主要集中在预防性护理和疼痛控制方面：多达 69% 的糖尿病神经病变患者接受了神经病理性疼痛的药物治疗。美国食品和药物管理局（FDA）确认了四种治疗糖尿病神经病变疼痛（PDN）的药物：普瑞巴林、度洛西汀、他喷他多和 8%辣椒素贴片。脊髓刺激（SCS）和经皮神经电刺激（TENS）等非药物疗法在减轻糖尿病患者疼痛方面都显示出良好的前景。尽管 PDN 给患者带来了沉重负担，但有效的治疗仍具有挑战性。本更新介绍了糖尿病神经病变的背景和管理，包括其流行病学、发病机制、预防护理和当前的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Pain and Headache Reports CLINICAL NEUROLOGY-

CiteScore

6.10

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings regarding the diagnosis, treatment, and management of pain and headache. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of pain and headache. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anesthetic techniques in pain management, cluster headache, neuropathic pain, and migraine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.